A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

NCT06343805 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis
Post-Essential Thrombocythemia Myelofibrosis
Post-Polycythemia Vera Myelofibrosis
PMF
PPV-MF
PET-MF

Interventions

DRUG: AJ1-11095

Sponsor

Ajax Therapeutics, Inc.